Thomas Luft1, Axel Benner2, Sonata Jodele3, Christopher E Dandoy3, Rainer Storb4, Ted Gooley4, Brenda M Sandmaier4, Natalia Becker2, Aleksandar Radujkovic5, Peter Dreger5, Olaf Penack6. 1. Medicine V, University Hospital Heidelberg, Heidelberg, Germany. Electronic address: thomas.luft@med.uni-heidelberg.de. 2. Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany. 3. Division of Bone Marrow Transplantation and Immunodeficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 4. Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA. 5. Medicine V, University Hospital Heidelberg, Heidelberg, Germany. 6. Charité University Medicine Berlin, Haematology, Oncology and Tumorimmunology, Berlin, Germany.
Abstract
BACKGROUND: Endothelial dysfunction links thrombotic microangiopathy to steroid-refractory graft-versus-host disease (GVHD) after allogeneic stem-cell transplantation. We aimed to assess if the simple formula-lactate dehydrogenase (U/L) × creatinine (mg/dL)/thrombocytes (109 cells per L)-termed the Endothelial Activation and Stress Index (EASIX), might be valuable for the prediction of death in patients with acute GVHD after allogeneic stem-cell transplantation. METHODS: For this retrospective analysis, we analysed a training cohort (in Germany) and three validation cohorts (in Germany and the USA) of patients with acute GVHD who had received consecutive allogeneic stem-cell transplantation. The primary endpoint was prediction of overall survival when measured at acute GVHD onset (EASIX-GVHD). We validated the prognostic strength of EASIX-GVHD for overall survival and non-relapse mortality in the three independent cohorts by calculating the prediction error (integrated Brier score), and concordance index. FINDINGS: In the total cohort of patients with acute GVHD (n=311), EASIX-GVHD predicted overall survival in univariable and multivariable models (univariate analysis, hazard ratio [HR] for a one-fold increase 1·16, 95% CI 1·12-1·20, p=0·0004). However, in the subpopulation of patients with myeloablative conditioning (n=72), EASIX-GVHD did not predict overall survival, which is probably attributable to thrombocytopenia at GVHD onset (73 × 109 cells per L [IQR 29·75-180·00] for myeloablative conditioning vs 160 × 109 cells per L [90·0-250·5] for reduced-intensity conditioning; p<0·0001). In patients who received reduced-intensity conditioning (n=239), EASIX-GVHD was a strong predictor of overall survival (HR for a two-fold change of 1·23, 95% CI 1·13-1·34; p<0·0001) and non-relapse mortality (cause-specific HR for a two-fold change of 1·24, 1·12-1·38; p<0·0001). Model validation for prediction of overall survival and non-relapse mortality by EASIX-GVHD was successful in two independent cohorts of adult patients with reduced-intensity conditioning (n=141, n=173) and in a cohort with mainly paediatric patients (n=89). INTERPRETATION: In patients with reduced-intensity conditioning, EASIX-GVHD is a powerful predictor of survival after GVHD. EASIX-GVHD could be the future basis for development of risk-adapted GVHD treatment strategies. FUNDING: There was no external funding source for this study.
BACKGROUND: Endothelial dysfunction links thrombotic microangiopathy to steroid-refractory graft-versus-host disease (GVHD) after allogeneic stem-cell transplantation. We aimed to assess if the simple formula-lactate dehydrogenase (U/L) × creatinine (mg/dL)/thrombocytes (109 cells per L)-termed the Endothelial Activation and Stress Index (EASIX), might be valuable for the prediction of death in patients with acute GVHD after allogeneic stem-cell transplantation. METHODS: For this retrospective analysis, we analysed a training cohort (in Germany) and three validation cohorts (in Germany and the USA) of patients with acute GVHD who had received consecutive allogeneic stem-cell transplantation. The primary endpoint was prediction of overall survival when measured at acute GVHD onset (EASIX-GVHD). We validated the prognostic strength of EASIX-GVHD for overall survival and non-relapse mortality in the three independent cohorts by calculating the prediction error (integrated Brier score), and concordance index. FINDINGS: In the total cohort of patients with acute GVHD (n=311), EASIX-GVHD predicted overall survival in univariable and multivariable models (univariate analysis, hazard ratio [HR] for a one-fold increase 1·16, 95% CI 1·12-1·20, p=0·0004). However, in the subpopulation of patients with myeloablative conditioning (n=72), EASIX-GVHD did not predict overall survival, which is probably attributable to thrombocytopenia at GVHD onset (73 × 109 cells per L [IQR 29·75-180·00] for myeloablative conditioning vs 160 × 109 cells per L [90·0-250·5] for reduced-intensity conditioning; p<0·0001). In patients who received reduced-intensity conditioning (n=239), EASIX-GVHD was a strong predictor of overall survival (HR for a two-fold change of 1·23, 95% CI 1·13-1·34; p<0·0001) and non-relapse mortality (cause-specific HR for a two-fold change of 1·24, 1·12-1·38; p<0·0001). Model validation for prediction of overall survival and non-relapse mortality by EASIX-GVHD was successful in two independent cohorts of adult patients with reduced-intensity conditioning (n=141, n=173) and in a cohort with mainly paediatric patients (n=89). INTERPRETATION: In patients with reduced-intensity conditioning, EASIX-GVHD is a powerful predictor of survival after GVHD. EASIX-GVHD could be the future basis for development of risk-adapted GVHD treatment strategies. FUNDING: There was no external funding source for this study.
Authors: Carlos Rondon-Clavo; Michael Scordo; Patrick Hilden; Gunjan L Shah; Christina Cho; Molly A Maloy; Esperanza B Papadopoulos; Ann A Jakubowski; Richard J O'Reilly; Boglarka Gyurkocza; Hugo Castro-Malaspina; Roni Tamari; Brian C Shaffer; Miguel-Angel Perales; Edgar A Jaimes; Sergio A Giralt Journal: Biol Blood Marrow Transplant Date: 2018-07-26 Impact factor: 5.742
Authors: Hao Dai; Olaf Penack; Aleksandar Radujkovic; David Schult; Joshua Majer-Lauterbach; Igor Wolfgang Blau; Lars Bullinger; Sihe Jiang; Carsten Müller-Tidow; Peter Dreger; Thomas Luft Journal: Bone Marrow Transplant Date: 2021-01-30 Impact factor: 5.483
Authors: Uri Greenbaum; Paolo Strati; Rima M Saliba; Janet Torres; Gabriela Rondon; Yago Nieto; Chitra Hosing; Samer A Srour; Jason Westin; Luis E Fayad; Hun J Lee; Swaminathan P Iyer; Ranjit Nair; Loretta J Nastoupil; Simrit Parmar; Maria A Rodriguez; Felipe Samaniego; Raphael E Steiner; Michael Wang; Chelsea C Pinnix; Christopher R Flowers; Sudhakar Tummala; Jeremy L Ramdial; Fevzi F Yalniz; Misha Hawkins; Katayoun Rezvani; Richard E Champlin; Elizabeth J Shpall; Sattva S Neelapu; Partow Kebriaei; Sairah Ahmed Journal: Blood Adv Date: 2021-07-27
Authors: Thomas Luft; Clemens-Martin Wendtner; Florentina Kosely; Aleksandar Radujkovic; Axel Benner; Felix Korell; Lars Kihm; Matthias F Bauer; Peter Dreger; Uta Merle Journal: Front Immunol Date: 2021-06-23 Impact factor: 7.561